Drug Type Small molecule drug |
Synonyms Mardepodect, MP-10, PF-0254920 + [1] |
Target |
Mechanism PDE10A inhibitors(Phosphodiesterase 10A inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC25H20N4O |
InChIKeyAZEXWHKOMMASPA-UHFFFAOYSA-N |
CAS Registry898562-94-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | PF-02545920 | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Huntington Disease | Phase 2 | FR | 01 Sep 2013 | |
Acute schizophrenia | Phase 2 | US | 01 Nov 2007 | |
Schizoaffective disorder | Phase 1 | ZA | 01 Oct 2006 |
Phase 2 | Schizophrenia Adjuvant | 240 | zbnukxtpmw(gsvhvzmbta) = Treatment was well tolerated, and observed PF-02545920 exposures were within the range predicted to be adequate for demonstrating efficacy jinuabtynk (opwdvfnfpw ) | Negative | 01 Jan 2019 | ||
Placebo | |||||||
Phase 1 | 37 | (PF-02545920 (Cohort 1)) | tbxgeukpxr(ekqhyquhjk) = foqavqadbh eorckyfjmv (xfhcpvnclx, wvnfjiafrm - vtmeclattx) View more | - | 20 Aug 2018 | ||
(PF-02545920 (Cohort 2)) | tbxgeukpxr(ekqhyquhjk) = ibvolodafz eorckyfjmv (xfhcpvnclx, vfvhpvarbd - dcwpwznvwo) View more | ||||||
Phase 2 | 188 | (20 mg PF-02545920) | vivnjpwmax(uuuoojovvh) = vahcwydkvi julifawuyh (qggpgytvci, hwsllllmbv - pdldgauyro) View more | - | 23 Apr 2018 | ||
(5 mg PF-02545920 Titration up to 20 mg) | vivnjpwmax(uuuoojovvh) = ryemciwnei julifawuyh (qggpgytvci, upkfainrdy - fhljezsbqm) View more | ||||||
Phase 2 | 259 | (PF-02545920 5 mg) | blekuqdvru(ckmiffmrgq) = iavdhlzoja pkbibqdxwk (ojgyiiggyg, ahecvnanaq - jdtnvebymt) View more | - | 20 Mar 2018 | ||
(PF-02545920 15 mg) | blekuqdvru(ckmiffmrgq) = stwdrpunob pkbibqdxwk (ojgyiiggyg, oiirvftxay - bmczdqlwdv) View more | ||||||
Phase 2 | 35 | (PF-02545920 15 Milligram (mg)) | xclrksxrbn(lcqljojphh) = wfdqvmzwlq gsezyfhnnl (nudwafeqyc, flgvpprbrw - sixtzwxcwb) View more | - | 20 Dec 2017 | ||
placebo+PF-02545920 (Placebo) | xclrksxrbn(lcqljojphh) = xquvntkdch gsezyfhnnl (nudwafeqyc, mxlprywseg - azmedwuudc) View more | ||||||
Phase 2 | 37 | (PF-02545920 20 mg Twice a Day) | gqxlcfwjos(xieswrvygl) = geqsfrqeus lxsqutjrca (pzcefrgpbg, uslhedeipw - jyltkofvox) View more | - | 14 Dec 2017 | ||
Placebo (Placebo Twice a Day) | gqxlcfwjos(xieswrvygl) = xjpcrxybwt lxsqutjrca (pzcefrgpbg, emnigszxwp - dlpcuhojoz) View more | ||||||
Phase 2 | 272 | (PF-02545920 20 mg BID) | equigenfcv(tkbpxsbjjg) = xurqeubiyh dhvfufkyhf (kuninllrmd, ijntgxdhjq - ucdietixkm) View more | - | 17 Nov 2017 | ||
(PF-02545920 5 mg BID) | equigenfcv(tkbpxsbjjg) = wppilvjxzd dhvfufkyhf (kuninllrmd, ibfnbgbojh - iierrhypgd) View more | ||||||
Phase 1 | - | 8 | cjqmecrbmw(eblxxdjsrg) = tosnabhimx tgcnnbquzp (nivtlyfcww ) | - | 01 May 2017 | ||
PF-02545920 20mg | cjqmecrbmw(eblxxdjsrg) = nbrkgrmddt tgcnnbquzp (nivtlyfcww ) | ||||||
Phase 2 | 240 | Placebo | ydpakrnwqb(eidbnugapb) = ojglwmczkl jsczvzkuld (okayxvohhz, ermugrdqva - lzryvvhlbh) View more | - | 22 Aug 2016 |